Blog

TissueGene Blog Post

Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea

Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea A huge congratulations to BioLife customer TissueGene / Kolon Life Science on their first patient use of CryoStor – powered Invossa, a novel cell-mediated therapy for degenerative arthritis. Invossa is the world’s first gene therapy for treating osteoarthritis of the knee, in which the cartilage that cushions…

Read More

BioLife Solutions Executes Supply Agreement with Celyad

BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers Proprietary Clinical Grade Cell Freeze Media Enables Long-Term Storage and Distribution of Engineered Cell-Based Therapies BioLife is pleased to announce that it has executed a long term supply agreement with NASDAQ-listed Celyad,…

Read More
TissueGene Blog Post

BioLife Solutions CryoStor® Cell Freeze Media Embedded in Invossa™: First Approved Cell and Gene Therapy for Osteoarthritis

Korean Approval Received by Kolon Life Science, TissueGene’s Exclusive Licensee BioLife Solutions, Inc. (NASDAQ: BLFS), the leading supplier of pre-formulated, clinical grade cell and tissue hypothermic storage and cryopreservation freeze media (“BioLife”), announced on July 13th 2017 that Kolon Life Science, TissueGene’s exclusive licensee for Asia, including Korea, has received marketing approval for Invossa-K Inj., the world’s…

Read More